Tirzepatide

Q: What should you monitor when using Tirzepatide?

Structure: Dual-acting peptide — agonist at both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptors. The dual mechanism provides more potent metabolic effects than GLP-1 alone. Dosage: Weight loss (titrate up): 2.5mg/week x4 weeks → 5mg/week x4 weeks → 7.5mg/week → 10mg/week → 12.

Dual GIP/GLP-1 receptor agonist. Mounjaro / Zepbound. More potent fat loss than Semaglutide in clinical trials. Increasingly popular in bodybuilding for cutting.

Overview

GLP-1

Dual GIP/GLP-1 receptor agonist. Mounjaro / Zepbound. More potent fat loss than Semaglutide in clinical trials. Increasingly popular in bodybuilding for cutting.

Effects on Markers

Significant appetite suppression, improves fasting glucose and HbA1c (more potently than Semaglutide), improves lipid profile, may mildly affect liver enzymes (typically improvement), can elevate amylase/lipase, reduces CRP and inflammatory markers

Compound Guide

Structure: Dual-acting peptide — agonist at both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptors. The dual mechanism provides more potent metabolic effects than GLP-1 alone.

Dosage:

Weight loss (titrate up): 2.5mg/week x4 weeks → 5mg/week x4 weeks → 7.5mg/week → 10mg/week → 12.5mg/week → 15mg/week
Bodybuilding cut: 5-10mg/week (titrate based on appetite suppression and tolerability)

Administration:

SubQ injection once weekly, abdomen/thigh/upper arm
Titrate slowly — at least 4 weeks at each dose level to minimise GI sides

Key Notes:

Clinical trials show greater weight loss than Semaglutide at maximal doses
Same GI side effect profile as Semaglutide but can be more pronounced during titration
Dual GIP/GLP-1 mechanism may better preserve muscle mass compared to GLP-1-only agonists (emerging data)
Extremely potent appetite suppression — some users struggle to eat enough protein
Maintain resistance training and high protein intake (>2g/kg) to preserve muscle
Monitor: fasting glucose, HbA1c, lipid panel, amylase/lipase, liver enzymes
Same pancreatitis risk considerations as Semaglutide

The monitoring panel for dual agonists, including the pancreatic and thyroid questions: GLP-1 bloodwork: what to test on semaglutide.

Usage History

Markers to Monitor

AST LDL CRP Glucose HbA1c Lipase

Pairs With

How Tirzepatide behaves when it is run alongside other compounds.

Commonly stacked with

Used to offset

Stacks the risk

Compare With

Tirzepatide vs Retatrutide

Retatrutide vs Tirzepatide: Which Triple-Agonist Wins

Tirzepatide vs Orforglipron (Foundayo)

Orforglipron vs Tirzepatide: Lilly's Pill vs Lilly's Injection

Frequently Asked Questions

Why Your HRV Is Low on TRT (Normal HRV by Age for Men)

Is an HRV of 25 low on TRT? Normal RMSSD by age for men, why wearables disagree, what testosterone, tren, clen and T3 do, and when low HRV matters.

Will Apitegromab (Isembyld) Build Muscle in Healthy Lifters?

Isembyld is the first approved myostatin blocker. No trial has ever measured muscle growth in a healthy adult, and the fracture signal is on the label.

When Will Orforglipron Be Available in Australia? (TGA Update)

Orforglipron (Foundayo) is not TGA approved yet; the Wegovy Pill is. Realistic Australian timeline, trial results, muscle loss and the bloodwork to run.

Is Imeglimin Better Than Metformin for Lifters?

Imeglimin (Twymeeg) is pitched as metformin plus MOTS-c plus NAD+. Here is what the trials show, what they don't, and the labs to run.